About Voyager Therapeutics
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's product pipeline includes programs for Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Its products include VY-AADC01 for Advanced Parkinson's Disease, VY-SOD101 for Monogenic amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich's Ataxia, VY-HTT01 for Huntington's Disease and VY-SMN101 for spinal muscular atrophy (SMA). VY-AADC01 consists of the AAV2 capsid, which has been used in multiple adeno-associated virus (AAV) gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the AADC transgene.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: VYGR
- Previous Close: $12.55
- 50 Day Moving Average: $12.05
- 200 Day Moving Average: $13.00
- 52-Week Range: $26,720,000.00 - $8.12
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.87
- P/E Growth: 0.00
- Market Cap: $332.40M
- Outstanding Shares: 26,720,000
- Beta: 4.04
- Net Margins: -195.31%
- Return on Equity: -20.58%
- Return on Assets: -15.23%
Companies Related to Voyager Therapeutics:
- Current Ratio: 9.96%
- Quick Ratio: 9.96%
What is Voyager Therapeutics' stock symbol?
Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."
Where is Voyager Therapeutics' stock going? Where will Voyager Therapeutics' stock price be in 2017?
6 equities research analysts have issued 12-month price objectives for Voyager Therapeutics' shares. Their predictions range from $11.00 to $37.00. On average, they expect Voyager Therapeutics' share price to reach $29.25 in the next twelve months.
When will Voyager Therapeutics announce their earnings?
Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 15th 2017.
What are analysts saying about Voyager Therapeutics stock?
Here are some recent quotes from research analysts about Voyager Therapeutics stock:
Cowen and Company analysts commented, "This morning VYGR released an update from VY-AADC01’s Ph Ib in Parkinson’s." (1/20/2017)
According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/18/2017)
Who owns Voyager Therapeutics stock?
Voyager Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.87%), Bain Capital Public Equity Management LLC (5.67%), Eventide Asset Management LLC (1.12%), Deerfield Management Co. (0.88%), State Street Corp (0.62%) and Harbourvest Partners LLC (0.14%).
Who bought Voyager Therapeutics stock? Who is buying Voyager Therapeutics stock?
Voyager Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Harbourvest Partners LLC, Bessemer Group Inc., Russell Investments Group Ltd., Aberdeen Asset Management PLC UK and State Street Corp.
How do I buy Voyager Therapeutics stock?
Shares of Voyager Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Voyager Therapeutics stock cost?
One share of Voyager Therapeutics stock can currently be purchased for approximately $12.44.